In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses some updates from the Phase II FORTE trial (NCT02203643), highlighting the progression-free survival (PFS) and overall survival (OS) observed, and the importance of applying PET-CT imaging in myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.